REG - Venture Life Group - Director/PDMR Shareholding

Venture LifeAnnouncement

04/06/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260604:nRSD9188Ga&default-theme=true

RNS Number : 9188G  Venture Life Group PLC  04 June 2026

4 June 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director/PDMR Shareholding

Venture Life (AIM: VLG), a recognised leader in proactive longevity, health
innovation and global commercialisation within the global consumer healthcare
sector, announces that Paul McGreevy, Non-Executive Chairman, purchased 88,273
ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary
Shares") on 3 June 2026 at a volume-weighted average price of 62.3 pence per
Ordinary Share.

Following the purchase, Mr McGreevy beneficially holds 1,052,098 Ordinary
Shares representing approximately 0.82 per cent. of the Company's issued share
capital.

 

For further information, please contact:

 

 Venture Life Group PLC                                    +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)      +44 (0) 20 7720 0500
 Stephen Keys / George Lawson / Joe Smith (Corporate Finance)

 Michael Johnson (Sales)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK, Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

The Company makes the following disclosure in accordance with article 19(3) of
the Market Abuse Regulation:

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Paul McGreevy

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chairman

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908
 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

Price       Volume
                                                                   61.6 pence  8,105

                                                            61.9 pence  8,066
                                                                   61.9 pence  8,066
                                                                   63.8 pence  15,663
                                                                   62.0 pence  48,373
 d)   Aggregated information                                       88,273 Ordinary Shares purchased at a volume-weighted average price of 62.3

                                                            pence.

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      3 June 2026

 f)   Place of the transaction                                     London Stock Exchange

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

88,273 Ordinary Shares purchased at a volume-weighted average price of 62.3
pence.

 

 

e)

 

Date of the transaction

 

3 June 2026

f)

 

Place of the transaction

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFFVLRAIVIIR



            Copyright 2019 Regulatory News Service, all rights reserved